Sarcopenia Market Expected to Reach USD 4.23 Bn by 2030

Sarcopenia Market Valued at USD 2.89 Bn in 2023, Expected to Reach USD 4.23 Bn by 2030 with a 5.6% CAGR. Aging population, increasing awareness about muscle-related diseases and increase in the need for sarcopenia treatment & intervention are some of the factors that are been driving the market.

Request Sample Link For More Details:https://www.maximizemarketresearch.com/request-sample/196035/

Drivers & Opportunities for Market Growth

There are several major factors that are driving growth of the exacerbating sarcopenia market. First, the world population is getting older at a rapid pace with the number of people over 60 years of age will increase significantly by the middle of the century. With age-associated sarcopenia occurs most frequently allowing for a greater expectations of trophic medical achievement entreaties against sarcopenia.

The key factor driving the growth of the sarcopenia market is the increasing awareness regarding sarcopenia among healthcare providers and patients, along with the aging population across the globe. As the emphasis on preventative medicine and healthy aging grows so too does the need for dietary supplements, pharmaceuticals, and physical therapy that can potentially buffer against the effects of sarcopenia.

Segmentation Analysis

Sarcopenia market is segmented into:Based on type: sarcopenia type 1 (primary sarcopenia and type 2 (secondary sarcopenia)Based on treatment: drug-based, exercise-based, nutrition-basedBased on geographical region: North America, Europe, Asia, Latin americas, and Middle east & Africa.

By Type: Primary sarcopenia and secondary sarcopenia. Primary sarcopenia occurs due to the normal aging process and secondary sarcopenia occurs due to diseases or conditions like cancer or diabetes or chronic diseases. Over the forecast period, the market size for sarcopenia associated with primary origin is anticipated to have the largest market share owing to large pool of geriatric population who may have high risk of developing sarcopenia.

Get to Know More About This Market Study: https://www.maximizemarketresearch.com/market-report/sarcopenia-market/196035/

Country Level Analysis

U.S.: The United States is the largest market for sarcopenia treatments, with the highest geriatric population and a well-established healthcare structure. The increasing incidence and awareness of sarcopenia, along with increasing government initiatives regarding geriatric health, drive the sarcopenia treatment and intervention market. Additionally, the presence of a robust pipeline of pharmaceutical companies developing drugs for sarcopenia is expected to fuel the market growth.

Germany: Germany is one of the prominent countries contributing to the European sarcopenia market owing to the country's emphasis on aging-related diseases and effective treatment. The demand for preventive and therapeutic solutions is driven by government-funded healthcare systems, and an increasing geriatric population requiring treatment for sarcopenia.

Japan:Japan now has one of the fastest-growing aging populations in the world, resulting in the global largest market of sarcopenia treatment within Asia Pacific region. Innovative therapies such as nutraceuticals and supplementary rehabilitation programs have been developed to be utilized by Japanese healthcare providers to manage the disease. In the country, the growth of the market is also aided by the priority that the government give to geriatric healthcare.

Competitor Analysis

The sarcopenia market is highly competitive and include several key players focused on the development of innovative therapies and treatments to meet the needs of individuals with this condition. Prominent companies involved in the sarcopenia market are Pfizer Inc, Novartis International AG, Bristol-Myers Squibb Company, AbbVie Inc and Astellas Pharma Inc.

Request Sample Link For More Details:https://www.maximizemarketresearch.com/request-sample/196035/

Pfizer Inc: Pfizer has been at the forefront of pharmacological treatments for sarcopenia (Compound) It is currently engaged in the clinical development of myostatin inhibitors and selective androgen receptor modulators (SARMs) for growth and strength in sarcopenic patients. Pfizer has long been a driving force in the precision medicine space, and the company has an extensive international footprint that allows it to capitalize on the market accurately.

Novartis International AG: Novartis is well advanced on the development of sarcopenia therapies, here it directly addresses targeted anabolic agents that have been shown to reverse muscle wasting. Regenerative medicine is another area where Novartis is strong, also something that is used to treat muscular diseases and aid in allowing patients to move and restore muscle strength.

Bristol-Myers Squibb Company: Bristol-Myers Squibb is engaged in the research and development of novel drug therapies for sarcopenia, including drugs that target inflammatory pathways and muscle regeneration. With over 125 programs and deep biopharmaceutical experience, the company positions itself to be a leader in the emerging market.

Conclusion

Sarcopenia Global Market is anticipated to grow at a favourable rate owing to rising ageing global population, driving the need for effective treatment and interventions for loss of muscle, which in turn is expected to boost the global sarcopenia market from 2023 to 2032. The advances in the development of pharmaceutical therapies, nutraceuticals, and physical rehabilitation allow interesting opportunities on the market for healthcare providers and product developers. Pfizer, Novartis, AbbVie and Astellas Pharma are at the forefront of this pressing health issue. Increased awareness of sarcopenia among patients and healthcare professionals will also lead relevant people to focus on maintaining muscle health which, in turn, would lead to a spur in the demand for unique sarcopenia solutions.

For additional insights, visit:

♦ Global Automotive Sensors Market https://www.maximizemarketresearch.com/market-report/automotive-sensors-market/13878/

♦ global Electric Vehicle Market https://www.maximizemarketresearch.com/market-report/global-electric-vehicle-market/1408/

♦ Electric Car Market https://www.maximizemarketresearch.com/market-report/global-electric-car-market/24473/

♦ Smart Railways Market https://www.maximizemarketresearch.com/market-report/global-smart-railways-market/39339/

♦ Smart Fleet Management Market https://www.maximizemarketresearch.com/market-report/iot-fleet-management-market/113398/

♦ Material Handling Robotics Market https://www.maximizemarketresearch.com/market-report/global-material-handling-robotics-market/66485/

♦ Global Automotive Interior Components Market https://www.maximizemarketresearch.com/market-report/global-automotive-interior-components-market/54725/

Contact Maximize Market Research:
MAXIMIZE MARKET RESEARCH PVT. LTD.
⮝ 3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
✆ +91 9607365656
🖂 sales@maximizemarketresearch.com
🌐 www.maximizemarketresearch.com

About Maximize Market Research:

Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

This release was published on openPR.